AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06047548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05558904
Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05048342
Drug: LOU064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
Trial: NCT05475808
Drug: Wrist local steroid injection
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance.
Trial: NCT06254261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04173650
Drug: AGLE 102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosomes from MSCs up to six administrations
Trial: NCT06109818
Drug: ICP-488 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-488 Placebo will be administered as tablet
Trial: NCT05012436
Drug: YHD1119 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose
Trial: NCT06264310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo SC injection
Trial: NCT05774639
Drug: Xolair Prefilled Syringe
RxNorm normalized name: Xolair Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
Trial: NCT06664502
Drug: EYE201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EYE201 solution for intravitreal administration
Trial: NCT06044090
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
Trial: NCT06044090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
Trial: NCT05139602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT04908423
Drug: Xeomin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
Trial: NCT06117046
Drug: Cardiopeptidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
Trial: NCT04829695
Drug: Artemether-lumefantrine drug combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
Trial: NCT04983368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
Trial: NCT04983368
Drug: Xanamem® 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily.
Trial: NCT05848687
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or NG.
Trial: NCT05848687
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, IM or PO
Trial: NCT05729568
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
Trial: NCT06503042
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
Trial: NCT05065372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
Trial: NCT05563675
Drug: Long acting muscarinic antagonists (LAMAs) in the evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAMAs administered at bedtime (8pm - 2am)
Trial: NCT04438213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Trial: NCT05738564
Drug: Epinephrine Inhalation Solution
RxNorm normalized name: Epinephrine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
Trial: NCT06177041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a minimum 2-hour IV infusion.
Trial: NCT06177041
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally twice daily (bid).
Trial: NCT05058287
Drug: Depo-Medrol 40Mg/Ml Suspension for Injection
RxNorm normalized name: Depo-Medrol 40mg/ml Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg Depo-Medrol mixed with hemostatic matrix
Trial: NCT05266027
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication, Nalbuphine Sebacate not contained
Trial: NCT04078139
Drug: The MP/RP group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Trial: NCT05080660
Drug: LY3526318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05080660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00002065
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05201469
Drug: Placebo for VIB4920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Trial: NCT05348993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05774275
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
Trial: NCT05774275
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
Trial: NCT04890431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
Trial: NCT05043558
Drug: beprostaglandin sodium
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beprostaglandin sodium
Trial: NCT04566666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of SCD-044 product
Trial: NCT04566666
Drug: SCD-044_Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCD-044 tablets in Dose 1.
Trial: NCT04566666
Drug: SCD-044_Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCD-044 tablets in Dose 2
Trial: NCT05816343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
Trial: NCT05479578
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05651932
Drug: Cohort A1 & A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTX-1001 will be administered orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
Trial: NCT05651932
Drug: Cohort C1 & C2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTX-1001: Orally for 28 days each cycle until progression Carfilzomib: IV, once weekly for 3 weeks in each 28-day cycle Dexamethasone: Orally once weekly
Trial: NCT05651932
Drug: Cohort D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTX-1001: Orally daily for 28 days each cycle until progression Pomalidomide: Orally, for 21 days in each 28-day cycle Dexamethasone: Orally once a week
Trial: NCT05639946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo drug
Trial: NCT05753033
Drug: SR750 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of SR750 orally
Trial: NCT05753033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of placebo orally
Trial: NCT05224141
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
Trial: NCT05821712
Drug: 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthwash
Trial: NCT05241431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets similar to active treatment.
Trial: NCT04680676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05443555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
Trial: NCT05802173
Drug: TDM-105795, 0.0025%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Trial: NCT05802173
Drug: TDM-105795, 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Trial: NCT06395688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft capsules (identical to active compound)
Trial: NCT05930951
Drug: OBT076
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
Trial: NCT05113394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual therapy
Trial: NCT04953052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An isotonic sterile solution
Trial: NCT06412315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
Trial: NCT06513884
Drug: HB-202/HB-201 alternating 2-vector therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Trial: NCT06513884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Trial: NCT05913388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice daily at 100mg.
Trial: NCT05482672
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral placebo will consist of corn starch and gelatin capsules
Trial: NCT05188222
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
Trial: NCT05613036
Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
Trial: NCT05613036
Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
Trial: NCT05843799
Drug: ILB-202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. infusion
Trial: NCT05843799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. infusion
Trial: NCT05223231
Drug: LBL-019 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial dose-MTD
Trial: NCT00021671
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06241456
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Trial: NCT06530563
Drug: Sufentanil Citrate
RxNorm normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.
Trial: NCT05220800
Drug: Iron(III)isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
Trial: NCT05220800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoton saline infusion
Trial: NCT06568783
Drug: [18F]-FAPI-74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Trial: NCT06218212
Drug: calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Trial: NCT04220203
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 orally two times per day on Days 1-14 of each 21-day cycle
Trial: NCT05031481
Drug: Venus 20 + 0,064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venus vaginal cream 20 + 0,064, single-dose.
Trial: NCT05497635
Drug: STSA-1002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05497635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05529940
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
Trial: NCT05357547
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-sucrose tablets in opaque capsule
Trial: NCT04896385
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Trial: NCT05129891
Drug: NNC0385-0434 B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet given orally
Trial: NCT05045833
Drug: SYN-020 Delayed Release Capsule
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration (by mouth)
Trial: NCT05561374
Drug: Low-dose OKN-007, BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
Trial: NCT05561374
Drug: Low-dose OKN-007, TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
Trial: NCT05561374
Drug: Mid-dose OKN-007, TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
Trial: NCT05561374
Drug: High-dose OKN-007, TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
Trial: NCT05895136
Drug: Standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT will be considered non-study medication and is not specified in the protocol.
Trial: NCT05476679
Drug: RZL-012+Medrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
Trial: NCT05476679
Drug: RZL-012+Celecoxib+Zyrtec
RxNorm normalized name: ZyrTEC
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
Trial: NCT05476679
Drug: RZL-012+facial and neck wrap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal Facial Band
Trial: NCT06328439
Drug: ANS014004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 7.5mg; 30mg QD/BID Oral
Trial: NCT05797168
Drug: AZD5335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Antibody-drug conjugate
Trial: NCT04950127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo.
Trial: NCT05688280
Drug: 1.0% IP-001 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
Trial: NCT04733144
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
Trial: NCT04948697
Drug: BAT1706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
Trial: NCT06543043
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06424834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken once orally daily.
Trial: NCT06355427
Drug: [18F]F-FAPI PET-CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
Trial: NCT04441034
Drug: Anti-convulsant medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-convulsants are very commonly used to treat patients with chronic pain.
Trial: NCT04441034
Drug: Anti-depressant medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-depressants are very commonly used to treat patients with chronic pain.
Trial: NCT06608472
Drug: Benicar HCT ® Tablets 40 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877